摘要
目的:通过观察人参皂苷Re干预后对淋巴管内皮细胞(LECs)血管内皮生长因子-C(VEGF-C)表达影响,探索人参皂苷Re促进淋巴管生成作用,为人参皂苷Re成为治疗淋巴水肿潜在药物提供依据。方法:使用CCK-8法测定不同浓度人参皂苷Re干预24 h后对LECs活性影响。运用ELISA方法检测细胞上清液中VEGF-C含量。采用RT-qPCR和Western blot方法,检测不同浓度人参皂苷Re干预下LECs VEGF-C mRNA及蛋白表达。通过划痕实验与成管实验,观察人参皂苷Re对LECs功能影响。结果:0~50μmol/L的人参皂苷Re干预24 h后对LECs活性无显著性影响。人参皂苷Re可以刺激VEGF-C mRNA表达,增加其蛋白表达及上清液中含量,同时促进LECs迁移和成管,并呈现出剂量依赖性。结论:人参皂苷Re通过刺激LECs VEGF-C表达,发挥促进淋巴管生成作用,是潜在治疗淋巴水肿药物。
Objective:To study the effects of ginsenoside Re on the expression of VEGF-C in lymphatic endothelial cells(LECs),to investigate the effects of ginsenoside Re on lymphangiogenesis,and to provide evidence for ginsenoside Re to become a potential drug for the treatment of lymphatic system-related diseases.Methods:LECs were treated with different concentrations of ginsenoside Re.After 24 h of intervention,the CCK-8 assay was used to determine the activity of LECs.The levels of VEGF-C in the cell supernatant were detected by ELISA.The expression level of VEGF-C was measured by RT-qPCR and Western Blot,and the function of LECs was showed by wound healing and tube formation assays.Results:The O~50μmol/L ginsenoside Re had no effect on the activity of LECs.Ginsenoside Re can stimulate VEGF-C mRNA,protein expression and supernatant content,and promote the migration and tube formation of LECs in a dose-dependent manner.Conclusion:Ginsenoside Re can promote lymphangiogenesis through stimulating the expression of VEGF-C in LECs.
作者
鲍嘉敏
徐浩
杭明辉
杨灿
王拥军
梁倩倩
BAO Jia-min;XU Hao;HANG Ming-hui;YANG Can;WANG Yong-jun;LIANG Qian-qian(School of Rehabilitation Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Spine Institute,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Key Laboratory of Theory and Therapy of Muscles and Bones,Ministry of Education of China,Shanghai 200032,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2022年第12期7018-7022,共5页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家重点研发计划(No.2018YFC1704300)
国家自然科学基金优秀青年科学基金项目(No.81822050)
上海市医学领军人才(No.2019LJ02)
上海市“曙光计划”项目(No.19SG39)
教育部创新团队发展计划项目(No.IRT1270)
科技部重点领域创新团队计划项目(No.2015RA4002)
上海市“重中之重”临床医学中心(No.2017ZZ01010)